News

Erasca Collaborates with Pfizer

Erasca, Inc., a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, announced a clinical trial collaboration and supply agreement (CTCSA) with Pfizer Inc. for the CDK4/6 inhibitor...

Nested Therapeutics Launches With $125 Million Financing

Nested Therapeutics, a biotechnology company pioneering a next-generation precision medicine platform to address hard-to-treat cancers that are founded on UCSF professor Kevan Shokat's technology, today announced the completion of a $90 million Series A financing led by the Life Sciences Investing...

Exai Bio Novel RNA-based Liquid Biopsy Platform May Detect Colorectal Cancer Early

Exai Bio, a next-generation liquid biopsy company, and researchers led by Professor Hani Goodarzi at UCSF are presenting data from a new study in a poster entitled "Serum-based colorectal cancer detection using orphan noncoding RNAs" at the 2022 European Society of Medical Oncology (ESMO) meeting.

Erasca Presents Promising Preliminary Phase 1 Monotherapy Data

Erasca, Inc., a clinical-stage precision oncology company founded by University of California chemical biologist Kevan Shokat, today announced promising preliminary Phase 1/1b monotherapy data for ERK1/2 inhibitor ERAS-007 and SHP2 inhibitor ERAS-601 in BRAF-driven and RAS/MAPK-altered solid tumors...

Arsenal Biosciences Closes $220 Million Series B Financing

Arsenal Biosciences, Inc. (ArsenalBio), a privately held programmable cell therapy company engineering advanced CAR T therapies for solid tumors founded on Medtech developed by Kole Roybal and Alex Marson at the University of California, San Francisco, today announced the close of a $220 million...

Talking Tech Transfer With Anthony Francis

With a career that already stretches decades, Francis has a lot of wisdom to share, such as the need to understand that universities and investors trade in different currencies: innovation and money. MORE

Trial Library Emerges Out of Stealth with $5 Million in Seed Funding

Fresh Capital Used to Build on Trial Library's Mission to Improve Health Equity by Expanding Access to Cancer Precision Medicine Spearheaded by Dr. Hala Borno, Leading UCSF oncologist and Health Equity Researcher. Press Release

Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion

The proposed acquisition brings leading sickle cell disease expertise to Pfizer with potential combined worldwide peak sales of more than $3 billion to address the full spectrum of critical needs in the underserved sickle cell community Transaction valued at $68.50 per Global Blood Therapeutics...

Mission Bio Launches Early Access Program That Can Detect Cancer in Individual Cells

 Mission Bio, Inc., the pioneer in high-throughput single-cell DNA analysis, today announced the initial availability of the industry’s first assay capable of determining measurable residual disease (MRD) in cancer down to the level of individual cells, launching a new era for the understanding of...

Sonoma Bio Clears FDA Hurdle

 Sonoma Biotherapeutics, an immune tolerance company focused on the development of novel regulatory T cell (Treg) therapies for autoimmune and inflammatory disease, today announced that the U.S.